What works in schizophrenia: Depot preparations may improve outcomes

From trainee to consultant, BMJ Group offers doctors around the world tailored information, special events, learning resources and recruitment services at every step along their career path.

... by doctors, for doctors, for patients
We are open for entries!

Online learning

BMJ Learning

High-quality CME / CPD for doctors and other healthcare professionals. BMJ Learning features hundreds of accredited, peer-reviewed learning modules in text, video, and audio formats. Find out more

Courses and Qualifications

BMJ Masterclasses

BMJ Masterclasses, led by experts, help clinicians to use the latest evidence and recent guidelines in practice and meet their CPD/CME requirements. Find out more

Exam Preparation

The leading provider of online exam preparation, helping over 167,000 healthcare professionals to pass their exams. Find out more

onExamination

Search all BMJ comment articles:

From

Limit by

Access to the full text of this article requires a subscription or payment. Please log in or subscribe below.

Peter M Haddad, consultant psychiatrist (Peter.Haddad@bstmht.nhs.uk),
Omair Niaz, specialist registrar in psychiatry

Sheffield Care Trust, Fulwood House, Sheffield S10 3TG
Bolton, Salford and Trafford Mental Health NHS Trust, Salford M30 0GT

EDITOR—The study by Tiihonen et al indicates that antipsychotics are not equally effective in treating schizophrenia.1 After a first admission with schizophrenia, patients treated with clozapine, olanzapine, or perphenazine depot had substantially lower risks of readmission, and discontinuation of treatment for any reason, than patients treated with oral haloperidol.

Credit: BSIP, PIKO/SPL

The increased effectiveness of clozapine is understandable in terms of its superior …